In Reply While we agree with the important points that Dr Bryant and colleagues have made about the role of multidisciplinary teams in improving adherence,1-4 we believe they may have misinterpreted our main thesis5 by inadvertently conflating adherence monitoring with adherence management. We have argued that input from pharmaceutical companies is essential to rectify the current lack of adherence monitoring. We do not, however, equate this with delivering overall adherence management, which is a far broader endeavor, needing to take into account multiple contributory factors and requiring an adequately resourced multidisciplinary approach, beyond the remit of any pharmaceutical company.
Hew M, Reddel HK. Monitoring Adherence to Inhaled Medications—Reply. JAMA. 2019;322(7):693–694. doi:10.1001/jama.2019.8654
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: